162 related articles for article (PubMed ID: 32293549)
1. The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations.
Alonso RS; Solari HP; de França Damasceno E; Burnier MNN; Ventura MP
BMC Pharmacol Toxicol; 2020 Mar; 21(1):24. PubMed ID: 32293549
[TBL] [Abstract][Full Text] [Related]
2. Chemotactic and chemokinetic properties of topical ophthalmic preparations.
Ozdal PC; Deschênes J; Rudzinski M; Antecka E; Baines MG
Curr Eye Res; 2002 Dec; 25(6):363-8. PubMed ID: 12789543
[TBL] [Abstract][Full Text] [Related]
3. Preservative-free
Duru Z; Ozsaygili C
Cutan Ocul Toxicol; 2020 Mar; 39(1):21-24. PubMed ID: 31615279
[No Abstract] [Full Text] [Related]
4. Effects of the preservative purite on the bioavailability of brimonidine in the aqueous humor of rabbits.
Dong JQ; Babusis DM; Welty DF; Acheampong AA; Tang-Liu D; Whitcup SM
J Ocul Pharmacol Ther; 2004 Aug; 20(4):285-92. PubMed ID: 15321023
[TBL] [Abstract][Full Text] [Related]
5. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
Ammar DA; Noecker RJ; Kahook MY
Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
[TBL] [Abstract][Full Text] [Related]
6. Formulation effects on ocular absorption of brimonidine in rabbit eyes.
Acheampong AA; Small D; Baumgarten V; Welty D; Tang-Liu D
J Ocul Pharmacol Ther; 2002 Aug; 18(4):325-37. PubMed ID: 12222763
[TBL] [Abstract][Full Text] [Related]
7. Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use.
Maruyama Y; Ikeda Y; Yokoi N; Mori K; Kato H; Ueno M; Kinoshita S; Sotozono C
Cornea; 2017 Dec; 36(12):1567-1569. PubMed ID: 28938378
[TBL] [Abstract][Full Text] [Related]
8. Sedative and physiological effects of brimonidine tartrate ophthalmic solution in healthy cats.
Ogata N; Kanda T; Kawahata M; Ichikawa T; Matsumoto Y; Morimitsu W; Nishino Y; Itoi T; Furumoto K
Vet Anaesth Analg; 2017 Sep; 44(5):1091-1100. PubMed ID: 28865952
[TBL] [Abstract][Full Text] [Related]
9. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
Benkali K; Leoni M; Rony F; Bouer R; Fernando A; Graeber M; Wagner N
Br J Dermatol; 2014 Jul; 171(1):162-9. PubMed ID: 24506775
[TBL] [Abstract][Full Text] [Related]
11. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.
Frampton JE
Drugs Aging; 2006; 23(9):753-61. PubMed ID: 17020399
[TBL] [Abstract][Full Text] [Related]
12. Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size.
Kesler A; Shemesh G; Rothkoff L; Lazar M
J Cataract Refract Surg; 2004 Aug; 30(8):1707-10. PubMed ID: 15313294
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and current applications of brimonidine.
Fudemberg SJ; Batiste C; Katz LJ
Expert Opin Drug Saf; 2008 Nov; 7(6):795-9. PubMed ID: 18983225
[TBL] [Abstract][Full Text] [Related]
14. Metal-organic frameworks, NH
Kim SN; Park CG; Huh BK; Lee SH; Min CH; Lee YY; Kim YK; Park KH; Choy YB
Acta Biomater; 2018 Oct; 79():344-353. PubMed ID: 30134206
[TBL] [Abstract][Full Text] [Related]
15. The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K; Kurokawa K; Kozai S; Kawamura A; Inada K; Tokushige H
Curr Eye Res; 2017 May; 42(5):748-753. PubMed ID: 27854122
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes.
Mundorf T; Wilcox KA; Ousler GW; Welch D; Abelson MB
Adv Ther; 2003; 20(6):329-36. PubMed ID: 15058750
[TBL] [Abstract][Full Text] [Related]
17. The dilution of benzalkonium chloride (BAK) in the tear film.
Friedlaender MH; Breshears D; Amoozgar B; Sheardown H; Senchyna M
Adv Ther; 2006; 23(6):835-41. PubMed ID: 17276951
[TBL] [Abstract][Full Text] [Related]
18. Effect of brimonidine tartrate 0.15% on scotopic pupil: controlled trial.
Gerente VM; Biondi AC; Barbosa CP; Lottenberg CL; Paranhos A
J Ocul Pharmacol Ther; 2007 Oct; 23(5):476-80. PubMed ID: 17900228
[TBL] [Abstract][Full Text] [Related]
19. High Permeability and Intercellular Space Widening With Brimonidine Tartrate Eye Drops in Cultured Stratified Human Corneal Epithelial Sheets.
Hashimoto Y; Yokoo S; Usui T; Tsubota Y; Yamagami S
Cornea; 2018 Feb; 37(2):242-247. PubMed ID: 29135708
[TBL] [Abstract][Full Text] [Related]
20. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine.
Cimolai N
Hum Exp Toxicol; 2020 Oct; 39(10):1279-1290. PubMed ID: 32347114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
